Share Name Share Symbol Market Type Share ISIN Share Description
Medgenics(Regs) LSE:MEDG London Ordinary Share USU582411158 COM SHS USD0.0001 (REGS)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 302.50p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -10.3 -58.6 - 14.86

Medgenics(Regs) Share Discussion Threads

Showing 301 to 323 of 325 messages
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
DateSubjectAuthorDiscuss
13/3/2014
07:14
There was a uk sell trade though on the day
buywell2
13/3/2014
05:57
do not sell the market makers have been reported to aim for this action same share par n par down 20% uk up 3% usa false market arb makers
jammytass
12/3/2014
16:43
why the drop today ?
buywell2
30/11/2012
09:53
Medgenics' INFRADURE enthuses hepatitis specialists Wed 3:25 pm by John Harrington "INFRADURE has the potential to provide a much more practical and patient-compliant way to attain sero-conversion or surface antigen loss in a large proportion of patients by having the patient's own tissue produce and deliver the protein instead of using injections." Experts at a medical conference in Boston have agreed that the INFRADURE treatment developed by Medgenics (LON:MEDG) has the potential to eliminate the hepatitis B virus. http://www.proactiveinvestors.co.uk/companies/news/50907/medgenics-infradure-enthuses-hepatitis-specialists-50907.html
lucky_punter
30/8/2012
07:06
AIM quoted Medgenics (LON:MEDG) is now preparing for the first 'in human' trial for the use of its INFRADURE technology in the treatment of hepatitis C. This comes as Israel's Ministry of Health approved its two proposed Phase I/II clinical trials today. http://www.proactiveinvestors.co.uk/companies/news/47456/medgenics-receives-approval-for-hepatitis-trial-plans-47456.html
lucky_punter
28/8/2012
07:17
has climbed a bit this last week (over the pond) http://quotes.wsj.com/MDGN/interactive-chart#P5D up 10% here today
andrbea
09/7/2012
09:51
) chief executive Dr. Andrew Pearlman says its Biopump technology has the potential to "start a whole new pharmaceutical industry". http://www.proactiveinvestors.co.uk/companies/news/45153/medgenics-demonstrates-biopump-technology-potential-as-it-enters-inflection-point-45153.html
lucky_punter
09/7/2012
08:55
SCANCELL'S BILLION DOLLAR VACCINE UP FOR GRABS http://www.euroinvestor.com/community/discussionthread.aspx?threadid=252803
northernlass
07/7/2012
22:57
* a bit too pricey * Yes, overpriced, hyped up, pumped and waiting for the dumping to start.
sueyou1
06/7/2012
23:15
Was gonna go to the proactiveinvestors presentations at Mayfair on Thursday night (which obviously included MEDG) but am only into Oilers & Goldies at the moment (just in BOR currently), so decided to give it a miss. Must have been a few eyebrows raised today by those that attended.. I went to the previous Thursday event mainly for the Tomco (TOM) presentation and was impressed by the AAU one (as well as Tomco's). Good luck here.. but a bit too pricey for me now !
georgio44
06/7/2012
13:59
wow what a rise !!!!!!!!!!!!!!
jammytass
06/7/2012
08:11
Medgenics CEO says a number of factors set the company at beneficial "tipping point" Dr Andy Pearlman, President CEO and Founder of Medgenics (AMEX:MDGN LON:MEDG), tells Proactiveinvestors that a number of things have come together: first validation of the clinical trial of EPODURE for the treatment of Sustained Anemia in Dialysis Patients, having been pushed by the US Food & Drug Administration straight into Phase II trials for its"biopump", it shows that the technology is safe and has "tremendous clinical benefit", second is the approval in Israel for a similar trial and then the attainment for a trial for MDGN's hepatitis biopump treatment. Andy also says that the appointment of Dr Sol Barer as Chairman of the board is excellent news. He says one cannot imagine a more "accomplished, famous and sought after leader in the biotechnology world" having started Celgene and building it up into a $25bln company. http://www.proactiveinvestors.co.uk/companies/stocktube/1229/medgenics-ceo-says-a-number-of-factors-set-the-company-at-beneficial-tipping-point-1229.html
ceohunter
05/7/2012
17:13
next step up very soon buy >>>>>>>>>>>>>> £7.50 to £10 plus on cards
jammytass
02/7/2012
15:51
Deltex Medical, e-Therapeutics, Medgenics and Cyan provide a change of diet at One2One Forum in London http://www.proactiveinvestors.co.uk/companies/news/44878/deltex-medical-e-therapeutics-medgenics-and-cyan-provide-a-change-of-diet-at-london-one2one-forum-in-london-44878.html
ceohunter
29/6/2012
16:39
Less than a ONE BAGGER :-)))))))))))))))))))))))))) Market Alert: RAY DIRKS Research Wall Street Rumblings Issue LIII May 20, 2012 by Ray Dirks Posted on admin on May 20, 2012 "Medgenics on Thursday announced that it received FDA (Food and Drug Administration) clearance to commence Phase IIb trial of Epodure for sustained anemia treatment in dialysis patients. The stock should sell at $17.00, or 3 times the its current price, within a year." http://www.cpreports.com/?p=2066 $17 = £ 10.8681 :-)))))))))))))))))))))))))) $17 = £ 10.8681 :-)))))))))))))))))))))))))) $17 = £ 10.8681 :-))))))))))))))))))))))))))
sueyou1
21/6/2012
13:24
Medgenics (LON:MEDG NYSE:MDGN) said it has received Orphan Drug Designation (ODD) from US regulator Food and Drug Administration for the INFRADURE Biopump to treat Hepatitis D. http://www.proactiveinvestors.co.uk/companies/news/44424/medgenics-gets-orphan-drug-designation-from-fda-for-biopump-technology-44424.html
lucky_punter
21/6/2012
13:22
Medgenics (LON:MEDG NYSE:MDGN) said it has received Orphan Drug Designation (ODD) from US regulator Food and Drug Administration for the INFRADURE Biopump to treat Hepatitis D. http://www.proactiveinvestors.co.uk/companies/news/44424/medgenics-gets-orphan-drug-designation-from-fda-for-biopump-technology-44424.html
lucky_punter
18/5/2012
10:52
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients. http://www.proactiveinvestors.co.uk/companies/news/42980/medgenics-cleared-by-fda-to-begin-phase-iib-clinical-trials-for-epodure-shares-up-42980.html
lucky_punter
30/4/2012
09:13
Bayer exec eager to conduct R&D in Israel Bayer's SVP and head of global clinical development Jörg Müller tells "Globes" why the company likes working in Israel. 24 April 12 18:34, Gali Weinreb "We collaborate with several Israeli companies," Bayer SVP and head of global clinical development Jörg Müller told "Globes" in an interview. "For example, with Medgenics Ltd. (AIM:MEDG; AMEX: MDGN) and Omri Laboratories, founded by Robert Taub. We have a hemophilia product that is one of the leaders in this field, and we continue to seek ways to improve its delivery. Medgenics is developing technology that enables patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of chronic diseases, which we are studying. Omri has developed a method for extending a substance's life so it can be injected less frequently. But a trial we conducted failed to show sufficient efficacy, so we decided to discontinue with them." http://www.globes.co.il/serveen/globes/docview.asp?did=1000743962&fid=1724
andrbea
08/2/2012
13:22
http://www.proactiveinvestors.co.uk/companies/news/38702/medgenics-poised-to-announce-major-progress-says-boss-38702.html Biopharmaceutical firm Medgenics (LON:MEDG, AMEX:MDGN) is poised to announce major progress for its novel protein delivery system, the Biopump, according to boss Andrew Pearlman. "We think we are in front of some very important developments in the next months," said president and chief executive Dr Pearlman in a recent interview with Wall Street newsletter website, corporateprofile.com.
lucky_punter
14/10/2011
14:58
Thanks TOPINFO, please join us on the current active thread though on: http://www.advfn.com/cmn/fbb/thread.php3?id=25557933
sicilian_kan
14/10/2011
14:02
DJ Medgenics Inc Research Update TIDMMEDG TIDMMEDU TIDMMEDG RNS Number : 2267Q Medgenics Inc 14 October 2011 October 14, 2011 UPDATE ON DEVELOPMENT OF FACTOR VIII BIOPUMP MISGAV, Israel and San Francisco (October 14th, 2011) - Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces an update to its previously announced agreement with Baxter Healthcare Corporation for the joint development of the Factor VIII Biopump which expired on September 30, 2011. The Company confirms that it is in active discussions with Baxter regarding the terms for possible further collaboration. The Company will provide a further update with regard to the outcome of such discussions as soon as it is able to do so. About Medgenics Medgenics is developing and commercializing Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins. Medgenics has three long-acting protein therapy products in development based on this technology: -- EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for 6 to more than 24 months; -- INFRADURE (planning to commence a Phase I/II trial in Israel in 1H12) to produce a sustained therapeutic dose of interferon-alpha for use in the treatment of hepatitis C; -- HEMODURE is a sustained Factor VIII therapy for the prophylactic treatment of hemophilia, now in development. Medgenics intends to develop its innovative products and bring them to market via strategic partnerships with major pharmaceutical and/or medical device companies. In addition to treatments for anemia, hepatitis C and hemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach $132 billion in 2013. Other potential applications for Biopumps include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity and diabetes. Forward-looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will, " "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur. For further information, contact: Medgenics, Inc. Phone: +972 4 902 8900
topinfo
26/7/2011
11:41
Noticed that the other day, typical plus really, totally inaccurate!
crimeprotection1
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20161205 00:31:41